Recent News

• 11.13.2025 - Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2026 Financial Results and Recent Updates
• 09.29.2025 - Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Recent Updates
• 09.25.2025 - Anebulo Pharmaceuticals Announces First Patients Dosed in Phase 1 Single Ascending Dose Study of Intravenous Selonabant, under Development for Acute Cannabis-Induced Toxicity
• 09.12.2025 - Anebulo Pharmaceuticals Announces Update on Going Private Transaction and Strategic Alternatives
• 07.23.2025 - Anebulo Pharmaceuticals Approves Plan to Terminate Registration of Its Common Stock

Recent Filings

• 10.14.2025 - SC 13E3/A Going private transaction by certain issuers
• 10.10.2025 - PRER14A Preliminary Proxy Soliciting materials
• 09.29.2025 - EX-99.1 EX-99.1
• 09.29.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 09.29.2025 - 8-K Current report
• 09.26.2025 - S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments
• 09.26.2025 - S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments
• 09.23.2025 - EFFECT Notice of Effectiveness
• 09.23.2025 - EFFECT Notice of Effectiveness
• 09.19.2025 - POS AM Post-Effective amendments for registration statement